HQY — HealthEquity, Inc.
Is HQY overbought or oversold? Here is the current MarketMoodz read.
HealthEquity, Inc. (HQY) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $104.58. The rating moved from Neutral to Overbought on November 13, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$104.58
- Last changeMoved from Neutral to Overbought on November 13, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all overbought Healthcare stocks →
AI analysis
HealthEquity, Inc. (HQY) benefits from durable secular adoption of HSAs and employer-driven consumer-directed health solutions, delivering recurring fee revenue and operating leverage potential. The company’s established platform and integrations give it competitive advantages for cross-sell and retention, while continued investment in digital services and partnerships can accelerate growth. Near-term performance is sensitive to membership growth cadence, competitive fee pressure, and investment income trends; regulatory changes or a major operational failure would be primary downside drivers. Overall, the balance of predictable cash flows and growth opportunities supports modest upside over the next month, with medium conviction given execution and policy risks.
Key factors
- Large and growing HSA/consumer-directed healthcare addressable market with secular tailwinds from higher healthcare costs and employer cost-shifting
- Recurring subscription and per-member fee revenue model provides predictable cash flows and potential operating leverage as membership scales
- Market position as an established HSA administrator and benefits platform with integrations across payroll, brokers and TPAs
- Potential upside from expanding services (ancillary benefits, digital tools, brokerage partnerships) and cross-sell to existing client base
- Relative insulation from direct insurer vertical-integration regulatory risk compared with fully integrated payors, but benefits from defensive flows into healthcare services
- Prudent balance sheet and historical cash generation support investment in growth initiatives and possible M&A to broaden product set
Risks
- Intensifying competition from incumbents (insurers, TPAs) and fintech/insurtech entrants that could compress fees or increase client acquisition costs
- Regulatory or policy changes affecting HSAs, tax treatment, or employer benefits that could slow adoption or reduce wallet share
- Pressure on investment income if interest rate environment shifts materially downward, reducing net yields on float/cash balances
- Execution risk on product expansion and technology investments; higher opex could weigh on margins if growth lags
- Data security/privacy incidents or operational outages could damage client relationships and incur remediation costs
- Macro/market volatility that reduces employer hiring or benefit take-up could slow membership growth in near term
See today's live rating, score and targets
Members see the live hourly rating for HQY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.